Long Non-Coding RNAs in Venous Thromboembolism: Where Do We Stand?

Venous thromboembolism (VTE), a common condition in Western countries, is a cardiovascular disorder that arises due to haemostatic irregularities, which lead to thrombus generation inside veins. Even with successful treatment, the resulting disease spectrum of complications considerably affects the patient's quality of life, potentially leading to death. Cumulative data indicate that long non-coding RNAs (lncRNAs) may have a role in VTE pathogenesis. However, the clinical usefulness of these RNAs as biomarkers and potential therapeutic targets for VTE management is yet unclear. Thus, this article reviewed the emerging evidence on lncRNAs associated with VTE and with the activity of the coagulation system, which has a central role in disease pathogenesis. Until now, ten lncRNAs have been implicated in VTE pathogenesis, among which MALAT1 is the one with more evidence. Meanwhile, five lncRNAs have been reported to affect the expression of TFPI2, an important anticoagulant protein, but none with a described role in VTE development. More investigation in this field is needed as lncRNAs may help dissect VTE pathways, aiding in disease prediction, prevention and treatment.

Automated summary

Venous thromboembolism (VTE), a common cardiovascular disorder in Western countries, is caused by haemostatic irregularities leading to thrombus formation in veins. Long non-coding RNAs (lncRNAs) may play a role in VTE pathogenesis, but their clinical usefulness as biomarkers and therapeutic targets for VTE management is still unclear. This article reviewed the current evidence on lncRNAs associated with VTE and the coagulation system, highlighting the need for further investigation in this field for disease prediction, prevention, and treatment.